Processa pharmaceuticals to conduct next generation chemotherapy-capecitabine phase 2 trial based on fda guidance and project optimus oncology initiative

Hanover, md, may 18, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”) today announces it has received guidance from the u.s. food and drug administration (“fda”) regarding the company's next trial for next generation chemotherapy-capecitabine (“ngc-cap”). the trial for ngc-cap, the combination of pcs6422 and capecitabine, will be a phase 2 safety-efficacy trial in colorectal cancer patients following the principles of fda's project optimus oncology initiative, the recent fda recommendation on how oncology drugs are to be developed going forward.
PCSA Ratings Summary
PCSA Quant Ranking